Scholars Central

Conference abstractPublished 13 May 2019

The end of phase 3 clinical trials in biosimilars development

Authors: Francois-Xavier Frapaise

FX Frapaise Pharma Consulting, France

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Most patients still have limited or no access to life-changing therapeutic proteins in the treatment of their cancer or autoimmune disorders. The current clinical development model of biosimilars is expensive, and in most cases, large phase 3 trials do not provide meaningful information on the clinical equivalence of biosimilars and reference compounds. At the same time, the development of state-of-the-art orthogonal analytical methods has enabled a better understanding of the structure and structureâ??function relationship of these biotherapeutics. Hence, we suggest here that a solid chemistry, manufacturing, and controls (CMC) package and meaningful phase 1 studies will leave limited uncertainty on bio similarity, which can be addressed, if needed, by post-approval, long-term follow-up studies (post-approval studies, pharmacovigilance, real world evidence data and registries, and possibly new post-approval models to be developed). We believe that this new approach may be more appropriate than 600- to 1000-patient, phase 3 trials in assessing biosimilarity and therapeutic equivalence. Obviously, there will probably never be a â??one size fits all” development model, and an individualized, risk-based approach to biosimilar development will always have to be considered and discussed early with regulators.

Subjects

Chemistry

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Chromatography & Separation Techniques
  • SubjectChemistry
  • BylineArticles whose byline prints “Francois-Xavier Frapaise”